

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL  
AT AS SOON AS POSSIBLE.**

LUD-5353.5 JEL/NDH (10016358)

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on June 7, 2002.

Fulbright & Jaworski L.L.P.

*Lanni Oles*

OFFICIAL

FAX RECEIVED

JUN 10 2002

GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant : Beatrice GAUGLER et al.  
Serial No. : 09/579,543  
Filed : May 26, 2000  
For : ISOLATED NUCLEIC ACID MOLECULES CODING FOR  
TUMOR REJECTION ANTIGEN PRECURSOR MAGE-4  
AND 41 AND USES THEREOF  
Art Unit : 1642  
Examiner : Alana Harris

#  
18/F  
PD  
6-11-02

June 7, 2002

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

S I R:

THIRD PRELIMINARY AMENDMENT

In connection with a telephone discussion with Supervisory Examiner Anthony Caputa, please amend this application as follows:

IN THE CLAIMS

Replace claims 38, 39, 40, 41, 43, 44, 58, 59, 60, 64 and 66 with the following:

Claim 38: An isolated nucleic acid molecule which encodes a tumor rejection antigen precursor expressed in melanoma cells, wherein the complementary sequence of said isolated nucleic acid molecule hybridizes to the nucleotide sequence set forth in SEQ ID NO: 13, 14 or 15 at 0.1XSSC, 0.1%SDS for 30 minutes, at 65°C.

F 1